G1 Therapeutics Investor Relations Material
Latest events
Q4 2023
G1 Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from G1 Therapeutics Inc
Access all reports
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company's lead product candidate is trilaciclib (G1T48), which is in Phase 3 clinical trial for use as a chemoprotective agent to mitigate the cardiopulmonary toxicity associated with chemotherapy comprising anthracycline and cyclophosphamide administered in the adjuvant, locally advanced or metastatic setting; and that is in Phase 1b/2 trial for use with carboplatin.
Key slides for G1 Therapeutics Inc
Corporate Presentation
G1 Therapeutics Inc
Corporate Presentation
G1 Therapeutics Inc
Latest articles
Remembering Daniel Kahneman: Transforming Psychology and Economics
Explore Daniel Kahneman's legacy in psychology and economics, highlighting his impact on decision-making and behavioral economics.
28 Mar 2024
Deere & Company: Shaping Agriculture & Construction Since 1837
Exploring Deere & Company: A global leader in agriculture & construction equipment since 1837.
28 Mar 2024
Jane Fraser: First Female Leader of a Major Wall Street Bank
Discover the journey of Jane Fraser, CEO of Citigroup and the first female leader of a major Wall Street bank.
28 Mar 2024
Ticker symbol
Country
🇺🇸 United States